Compare TG Therapeutics Inc (TGTX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Weibo Corp — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Weibo Corp trades at $6.54 (market cap $1.56B). The key difference: TG Therapeutics Inc is far larger — about 5.2× Weibo Corp's market cap, and Weibo Corp pays a 9.47% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Weibo Corp for 102 Days on average.
| TGTX | WB | |
|---|---|---|
Market Cap | $8.16B | $1.56B |
Volume | 1,735,121 | 812,503 |
Sector | Health | Media |
52-Week High | $59.06 | $12.37 |
52-Week Low | $26.94 | $6.33 |
Typical Hold Time | 16 Days | 102 Days |
Enterprise Value | $8.37B | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Weibo (WB) trades at $6.54, up 0.93% with bearish technical signals despite attractive valuation metrics including a P/E of 5.32 and P/B of 0.4. The company reported mixed Q2 2026 earnings with a beat on EPS but faces declining user metrics and advertising challenges. Net cash flow turned negative in 2024 at -$694M before recovering to $408M in 2025, while revenue has remained stagnant around $1.8B annually.
WB presents as a deep-value play with strong profitability margins but limited growth visibility. The stock's upside depends on advertising recovery and user engagement stabilization, though competitive pressures and China's regulatory environment pose significant risks. Analyst consensus is divided with 41% buy ratings, reflecting uncertainty about the company's ability to reignite growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
